Yale Cancer Center Immuno-Oncology Symposium 2019
Challenges to Precision Medicine for Anti-Cancer Immunotherapy: When Other Combos w/ Anti-PD-1 Are Active, Mechanisms May Be Redundant w anti-CTLA-4
Login to view comments.
Click here to Login
Videos